Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, is featured in a report issued by PCG Digital Holdings LLC, an affiliate of PCG Advisory Inc. In the report, PCG noted that “Lexaria, delivering active ingredients to patients, could deliver for investors too.” The report stated that LEXX may be poised for a surge as the company’s DehydraTECH(TM) platform has proven to be an effective way to deliver active ingredients. The release noted that DehydraTECH had shown effectiveness as a hypertension treatment using CBD as well as with various antivirals. In addition, the release reported that DehydraTECH-enabled products are currently available in more than 7,000 retail outlets located throughout the United States and that the “book-to-market ratio suggests a great deal of confidence in management.” PCG observed that “LEXX was on an upward trend and trading around $8.50 per share in mid-July, about a dollar away from a 12-month peak. That momentum gave investors the confidence to exercise another $3.8 million in existing warrants and, with the risk of dilution setting in, the stock price retreated to about $5.50. Considering Lexaria’s market cap is still almost $30 million, maybe a one-third drop in share price is a bit too excessive a reaction compared to only a one-tenth expansion in share dilution. And the company appears to have about $12 million in cash, roughly $2 per share. The fundamentals have only changed for the better over the past few months. The company operates an in-house research laboratory and holds a robust intellectual property portfolio with 21 patents granted and over 50 patent applications pending around the world. The company is vertically integrated with subsidiaries in the hemp, oral nicotine, and pharmaceutical industries. It should also be noted that the July stock price surge came on the news of DehydraTECH’s efficacy in connection with a colchicine, a COVID-19 therapy.”
To view the full press release, visit https://cnw.fm/oS5SE
About Lexaria Bioscience Corp.
Lexaria Bioscience’s proprietary drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The company’s technology can be applied to many different ingestible product formats including foods, beverages, oral suspensions, tablets and capsules. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption of cannabinoids and nicotine by up to 5 to 10 times, reduce time of onset from one to two hours to minutes, and mask unwanted tastes; the technology is planned to be further evaluated for orally administered bioactive molecules including anti-viral drugs, vitamins, nonsteroidal anti-inflammatory drugs (NSAIDs) and more. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 21 patents granted and more than 50 patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is part of the InvestorBrandNetwork.
